Phase 2
N=110
Cognitive Remediation for Cocaine Dependence
Cocaine Dependence
Bottom Line
View on ClinicalTrials.gov: NCT01393457 ↗Enrolled (actual)
110
Serious AEs
3.6%
Results posted
Mar 2018
Primary outcome: Primary: Cocaine Use Based on Urine Drug Screening — 20.36; 15.57; 22.3; 27.8 number of negative drug screens
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- levodopa/carbidopa (Drug); Ropinirole 2 mg/d (Drug); Placebo (Drug); Ropinirole 4 mg/d (Drug)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- The University of Texas Health Science Center, Houston
- Primary completion
- Feb 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cocaine Use Based on Urine Drug Screening |
20.36; 15.57; 22.3; 27.8 | — |
| SECONDARY Number of Participants Who Completed the 10 Week Trial |
14; 14; 16; 15 | — |
Summary
The purpose of this study is to evaluate treatments designed to improve cocaine treatment success by combining medications that target cocaine-related cognitive impairments.
Eligibility Criteria
Inclusion Criteria
- meet criteria for cocaine dependence
- seeking treatment for cocaine dependence
- be in acceptable health based on medical history and physical exam
Exclusion Criteria
- dependent on drugs other than cocaine, nicotine, marijuana
- have a medical condition contraindicating treatment with study medications
- having conditions of probation or parole requiring reports of drug use to officers of the court
Data sourced from ClinicalTrials.gov (NCT01393457). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.